Is BioLineRx Ltd. (BLRX) a Buy, Sell, or Hold?
NASDAQ : BLRX
BioLineRx Ltd.
$2.9 USD
-$0.08 (-2.68%)
- Volume
- 5.95K
- Average Volume
- 53.96K
- Market Capitalization
- $12.62M
- P/E Ratio
- -1.28
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $4.75
- Year Low
- $2.15
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.58
Company Overview
NASDAQ
Philip A. Serlin
Biotechnology
Healthcare
BLRX
20
IL
USD
Liquidity Metrics
0.54
1.58
1.43
0.18
0.00
Sales & Valuation
$1.19M
8.56
0.74
-1.51
-0.04
Profitability
-$0.29
-$1.18M
-633.83%
-697.32%
-47.86%
-22.97%
P/E Metrics
-1.28
0.00
0.00
Analyst Price Target & Rating
2/5
7 Analysts
%
Poll Results
About BioLineRx Ltd. (NASDAQ:BLRX) Stock
BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer. This compound is currently progressing through Phase 2 studies for metastatic pancreatic adenocarcinoma and Phase 1b trials for acute respiratory distress syndrome linked to COVID-19 and other viral infections. Additionally, Motixafortide is being investigated for its therapeutic potential in solid tumors and acute myeloid leukemia. The company's pipeline also includes AGI-134, an immuno-oncology agent ... presently undergoing Phase 1/2a clinical evaluations for various solid tumors. Furthermore, BioLineRx is advancing BL-5010, a custom-designed, proprietary pen-like device intended for the non-surgical removal of skin lesions. BioLineRx maintains strategic alliances, notably a collaboration with MSD in the domain of cancer immunotherapy, and an agreement with MD Anderson Cancer Center to explore Motixafortide combined with KEYTRUDA (pembrolizumab) for pancreatic cancer. They also have a licensing deal with Perrigo Company plc for the over-the-counter sale of BL-5010.
2026-07-08 07:00:00
Synergy was demonstrated in a combination arm of GLIX1 and the PARP inhibitor olaparib at low doses, with substantially better efficacy compared to the control arm and compared to each drug individually at its optimal dose GLIX1 in combination with olaparib also showed comparable efficacy to that seen with the chemotherapy drug cisplatin Results reinforce synthetic lethality between GLIX1 and PARP inhibitors, indicating that GLIX1 can broaden the use of PARPi in ovarian cancer TEL AVIV, Israel and OSLO, Norway, July 8, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced highly encouraging new preclinical data demonstrating strong synergy between GLIX1 and PARP inhibitors in a patient-derived xenograft (PDX) model of ovarian cancer.
BioLineRx Ltd. (BLRX) Q1 2026 Earnings Call Transcript
2026-05-27 10:47:04
BioLineRx Ltd. (BLRX) Q1 2026 Earnings Call Transcript
BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-27 07:00:00
- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) - - Announced new GLIX1 data demonstrating potent anti-tumor effect in GBM across multiple in-vivo studies, including a temozolomide (TMZ)-resistant patient-derived xenograft model - - Management to host conference call today, May 27, at 8:30 am EDT - TEL AVIV, Israel, May 27, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended March 31, 2026, and provided a corporate update.
2026-05-22 07:00:00
TEL AVIV, Israel and OSLO, Norway, May 22, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that two abstracts featuring GLIX1 will be published at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, which is being held May 29-June 2, 2026, in Chicago, IL.
BioLineRx to Report First Quarter 2026 Results on May 27, 2026
2026-05-20 07:00:00
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, May 20, 2026 /PRNewswire/ -- BioLineRx Ltd.
2026-05-19 07:00:00
New preclinical data further demonstrate GLIX1's robust efficacy in a dose-dependent manner, with strong anti-tumor activity observed even at the lowest doses tested Results highlight GLIX1's potential to address the high unmet need for patients with GBM TEL AVIV, Israel and OSLO, Norway, May 19, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced highly encouraging new preclinical data that further support the recently initiated Phase 1/2a clinical trial evaluating GLIX1 for the treatment of recurrent and progressive GBM and other high-grade gliomas.
2026-04-28 07:00:00
Patient was dosed at NYU Langone Health under the supervision of Dr. Alexandra Miller, Chief of Neuro-Oncology & Co-Director of Brain and Spine Tumor Center, Perlmutter Cancer Center Data from the Phase 1 part of the study anticipated in H1 2027 TEL AVIV, Israel, and OSLO, Norway, April 28, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that the first patient has been dosed in the first-in-human, Phase 1/2a study of GLIX1 for the treatment of recurrent and progressive glioblastoma (GBM) and other high-grade gliomas.
Frequently Asked Questions
-
What is the current BioLineRx Ltd. (BLRX) stock price?
-
BioLineRx Ltd.(NASDAQ:BLRX) stock price is $2.9 in the last trading session. During the trading session, BLRX stock reached the peak price of $4.75 while $2.15 was the lowest point it dropped to. The percentage change in BLRX stock occurred in the recent session was --2.68% while the dollar amount for the price change in BLRX stock was -$0.08.
-
BLRX's industry and sector of operation?
-
The NASDAQ listed BLRX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BLRX?
-
Mali Zeevi | Chief Financial Officer
Ella Sorani | Chief Development Officer
John Lacey | Head of Corporation Communications & Investor Relations
Philip A. Serlin | Chief Executive Officer
Raziel Fried | Treasurer & Budgetary Control Director -
How many employees does BLRX have?
-
Number of BLRX employees currently stands at 20. BLRX operates from Modi’in Technology Park, Hevel Modi'in, HM 7177871, IL.
-
Link for BLRX official website?
-
Official Website of BLRX is: https://www.biolinerx.com
-
How do I contact BLRX?
-
BLRX could be contacted at phone #972 8 642 9100 and can also be accessed through its website. BLRX operates from Modi’in Technology Park, Hevel Modi'in, HM 7177871, IL.
-
How many shares of BLRX are traded daily?
-
The average number of BLRX shares traded daily for last 3 months was 53.96K.
-
What is the market cap of BLRX currently?
-
The market value of BLRX currently stands at $12.62M with its latest stock price at $2.9